Increased cancers after mRNA vaccines

COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province

The rate of first hospitalization for cancer of any site

Unvaccinated group: 0.85%

Vaccinated group (one or more doses): 1.15%

N = 296,015 population

Hospital admission with a cancer diagnosis, 3,124

(p less than 0.001).

Vaccination with at least one dose

Colon-rectal cancer HR: 1.34

Breast cancer HR: 1.54

Bladder cancer HR: 1.62

After three or more vaccine doses

Breast cancer HR: 1.36

Bladder cancer HR: 1.43

All significant

After one dose (180 days after)

Rate of first hospital admissions for cancers

All cancers: up 23% significant

Colorectal: up 34% significant

Lung: down = 10%

Breast: up 54% significant

Uterine: up = 75%

Ovarian: up = 65%

Prostate: up = 1%

Bladder: up 62% significant

Thyroid: up =58%

Haematological: up = 33%

After three dose (180 days after administration of third dose)

All cancers: up = 9%

Colorectal: up = 14%

Lung: down = 5%

Breast: up=36% significant

Uterine: up = 20%

Ovarian: up = 86%

Prostate: down = 3%

Bladder: up=43% significant

Thyroid: down = 3%

Haematological: up = 5%

More about the study

Population-wide cohort analysis

Evaluating the risk of all-cause death and cancer hospitalization by SARS-CoV-2 immunization status.

National Health System official data, entire population, Pescara province, Italy

Followed from June 2021 (six months after the first vaccination) to December 2023.

296,015 residents aged ≥11 years

Hospital admission with a cancer diagnosis, 3,124

16.6% were unvaccinated

83.3% received ≥1 dose

62.2% ≥3 doses.

Compared with the unvaccinated, those receiving ≥1 dose showed a significantly lower likelihood of all-cause death

Cancer hospitalization was significant only among the subjects with no previous SARS-CoV-2 infection

Some cancer risks went down after 1 year (relative to 180 days)

(But breast, ovarian and bladder went up at one year relative to 180 days after 1 vaccine dose)

Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.